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ABSTRACT 26 
 27 
Background  28 
National Tuberculosis Programmes(NTP) require specialist input to support the development 29 
of evidence informed policy and practice, typically against tight deadlines. 30 
 31 
Aim  32 
Describe lessons learned from establishing a dedicated Tuberculosis Think Tank(TT) to 33 
advise the South African NTP on Tuberculosis(TB) policy. 34 
 35 
Intervention and evaluation methods 36 
A national TB TT was established to advise the NTP to support evidence based policy. Support 37 
was provided for activities including: meetings, modelling, and regular calls with a wider 38 
network of unpaid expert advisers under an Executive Committee and Working Groups. 39 
Intervention evaluation used desktop analysis of documentary evidence, interviews, and direct 40 
observation. 41 
 42 
Results 43 
The TB TT evolved over time into three key roles, an ‘Institution’, a ‘Policy Dialogue Forum’, 44 
and an ‘Interface’. Although enthusiasm was high, motivating participation from NTP and 45 
external experts proved challenging. Motivation of working groups was most successful when 46 
aligned to a specific need for NTP decision-making. Despite challenges, the TB TT contributed 47 
to South Africa’s first ever TB&HIV investment case, and the decision to create South Africa’s 48 
first ever ring-fenced grant for TB. The TB TT also assisted the NTP in formulating strategy to 49 
accelerate progress towards the WHO Targets. 50 
 51 
Discussion 52 
The TB TT, with partners, yielded major successes in supporting evidence-informed decision 53 
making, and garnered increased funding for TB in South Africa. Identifying ways to increase 54 
involvement of NTP staff & other experts, and keeping the scope of the TT well defined, could 55 
facilitate greater impact. TT initiatives could be replicated in other settings to support evidence-56 
informed policymaking. 57 
  58 
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BACKGROUND 59 
Tuberculosis (TB) presents a major health burden in South Africa (1).  In response to this, and 60 
with considerable recent political support (2-4), South Africa’s National TB Programme (NTP) 61 
has become an early adopter of innovation (5). However, resources are limited and the NTP 62 
requires specialist input to support development of policy and practice, typically against tight 63 
deadlines.  64 
   65 
International bodies such as the World Health Organization (the WHO) provide global TB 66 
guidance documents and periodic country epidemiological reviews, but these global bodies 67 
cannot provide the rapid, bespoke advice that the South African, and other NTP’s, often 68 
require (6).  69 
 70 
As such, a dedicated ‘TB Think Tank’ (TB TT) was conceived by the NTP to fill the gap, 71 
drawing on existing national expertise and research capacity, and international networks. It 72 
was tasked with anticipating and responding to policy makers’ requests for evaluation of 73 
evidence and quantitative analysis, and with improving TB data utilization.   74 
 75 
The need for rapid, bespoke advice is not unique to South Africa or Tuberculosis. Advisory 76 
bodies and agencies have been created in many countries globally to fill this advice gap in 77 
low/middle (7-9) and high income counties (10).  In South Africa itself, an HIV TT exists, tasked 78 
with ‘providing a central place for all stakeholders [under Department of Health], to review 79 
epidemiological, routine monitoring and economic evidence related to the HIV epidemic, 80 
identify priority gaps, and establish consensus on appropriate next steps, including research 81 
projects and pilots of new programs and policies’ (11). However, very little has been written 82 
about the structure and effectiveness of health policy TTs (8, 12-14). Reviewing this literature, 83 
Bennett et al concluded that small number of key factors were key to the success of health 84 
policy TTs: production of timely, relevant, credible, trustworthy and actionable evidence, and 85 
close relationships with policy makers (12). In their in-depth analysis of six health policy TTs 86 
in Bangladesh, Ghana, India, South Africa, Uganda and Vietnam, Bennet et al also concluded 87 
that a supportive policy environment, some degree of independence from government, and 88 
strong links to policy makers were critical for effective policy engagement. A study on the 89 
formation of a TT-like institution in Indonesia identified challenges that included: longer-term 90 
financial support, a limited number of scientific publications, and difficulties in documenting TT 91 
impact on programmatic performance (9). 92 
 93 
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To contribute to this critical, but limited, literature, the aim of this paper was to describe the 94 
lessons learned from establishing a dedicated TB TT to advise the South African NTP on TB 95 
policy.  96 
  97 
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INTERVENTION AND EVALUATION METHODS 98 
 99 
INTERVENTION 100 
Mission and structure 101 
The mission of the TB TT was to advise the NTP on TB treatment and prevention policy and 102 
programmatic implementation, to achieve the National Strategic Plan (NSP)/World Health 103 
Assembly targets for TB with focus on innovations. The TB TT’s internal structure evolved 104 
over time and its current organizational structure is shown in Figure 1. The TT was co-chaired 105 
by the Deputy Director General for Health Strategy and the head of a SA research institute. 106 
The TT was created to include an Executive Committee and three expert working groups. The 107 
three expert working groups were each chaired by two or more co-chairs including: an 108 
individual from the NTP and another individual (or two) from domestic expert organisations. 109 
 Working group 1:  Modernising a national response to TB aligned to the Post-2015 110 
Global TB programme Strategy, including 111 
o Know your epidemic (systematic analysis of data) 112 
o Define your interventions: e.g. access to care, and active case finding 113 
o Plan your response (including modelling and economics) 114 
 Working group 2: Implementation and Delivery, including 115 
o Information and communication technologies, monitoring and evaluation, 116 
and surveillance 117 
o Forecasting and budgeting 118 
o Monitoring implementation of new policy 119 
o Human resources planning and training 120 
 Working group 3: Research on diagnostics, drugs and vaccines 121 
 122 
The SA Government Health and Finance departments were at the core of the TT, supported 123 
by South African and international research institutions, including the Department of Science 124 
and Technology, the South Africa Medical Research Council, London School of Hygiene and 125 
Tropical Medicine, technical support agencies, funders & WHO Global TB Programme and 126 
UNAIDS.  127 
 128 
Objectives 129 
The wider project supporting the TT had five main objectives: 1) Formalizing the TB TT; 2) 130 
Creating and applying epidemiological and economic modelling tools in order to identify cost-131 
effective and affordable strategies to assess, and reach, NSP goals; 3) Promoting the use of 132 
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the quantitative evidence generated by these tools, to inform TB prevention and care policy 133 
and practice in South Africa; 4) Building capacity and sustainable systems to ensure the tools 134 
can be used within country to inform TB prevention and care policy and practice; and 5) 135 
Assessing the success of the project disseminating findings, and if successful, identifying 136 
funding to support systems beyond the end of project. 137 
 138 
Activities and resources 139 
The TB TT was designed to consider policy and implementation questions requiring evidence 140 
to inform policy by carrying out the following activities: 1) Collating, reviewing, synthesizing 141 
and evaluating evidence, 2) Requesting evidence, and if necessary, commissioning research, 142 
3) Brainstorming innovations & making recommendations to the NTP for policy and 143 
implementation in the form of policy briefs, 4) Assisting NTP in developing operational 144 
guidelines, and 5) Advising NTP on key implementation activities in support of budget 145 
discussions with the National Treasury and as part of investment case development for new 146 
donor grants.  The TT was set up with financial support from the Bill and Melinda Gates 147 
Foundation (BMGF). This funded quarterly face-to-face TT meetings, the dedicated 148 
epidemiological modelling and economic staff (~3.5 people), and convening of regular calls 149 
with a wider network of unpaid expert advisers in the Executive Committee and the three area 150 
Working Groups.  The Box illustrates the TT activities for the example of childhood screening 151 
for TB. 152 
 153 
Operating modes 154 
The TT was established flexibly to operate through two modes: 1) to respond to specific, 155 
usually time limited, requests from the NTP and 2) to serve as thought drivers for large national 156 
strategy development processes such as the new five-year NTP Strategy. 157 
 158 
EVALUTION METHODS 159 
This BMGF project was evaluated by an independent external evaluator (DC) based on desk-160 
top analysis of documentary evidence, interviews, and direct observation.  161 
The main audience was the project sponsors (the funder and the NTP) and other key 162 
stakeholders. However, the evaluation was also designed to provide the project team with 163 
regular constructive feedback to help improve the likelihood of a successful outcome.  It 164 
recognised that the project’s evolutionary nature and organisational change themes were 165 
often best supported though an ‘appreciative inquiry’ approach, focusing more on identifying 166 
and building on what was working well and less on correcting problems or deviations from the 167 
detail of the original proposal. The funder was amenable to this approach. 168 
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The evaluator’s synthesis of the evidence and his conclusions and recommendations were 169 
published in his March 2017 Final Evaluation Report, which drew on: 170 
 Baseline interviews during June-September 2014 with project team members and external 171 
stakeholders and a review of project documents (Interim Report 1).  172 
 Project team interviews and a review of progress reports during July-December 2015 173 
(Interim Report 2).  174 
 Participant interviews and observation of the December 2015, April 2016, and August 2016 175 
TB TT and NTP workshops (Interim Reports 2 and 4).  176 
 An analysis of think tank models and evolving TB TT roles (Interim Report 5). 177 
 Final evaluation interviews November-December 2016 with project sponsors, international 178 
and national stakeholders, project team members and an audit of project management 179 
documentation and procedures. 180 
All interviews were non-attributable. The project team was invited to comment on factual 181 
accuracy before publication, but the evaluator retained complete discretion over their 182 
inclusion. The recommendations included in this paper were based on the findings from the 183 
evaluator’s external evaluation. 184 
  185 
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RESULTS AND LESSONS LEARNED 186 
Main achievements 187 
The TT, with partners, yielded several major successes over the first three years (Table 1).  188 
Soon after the TT was launched, impact modelling, carried out by modellers supporting the 189 
TT, was used to help define the scope of a SA MRC/UK MRC funding call on operational 190 
research with a budget of R70m. In 2015, the TT supported the establishment of the National 191 
TB Research Plan and Investment Case for TB Research, by convening meetings and 192 
developing the initial concept note. Also in 2015, the TT provided evidence supporting the 193 
creation of SA’s first ever joint TB & HIV Investment Case. This led to changes in NTP budgets 194 
for TB in 2016, and formed the basis of Intensified Case Finding recommendations in the new 195 
NTP strategy. In 2016, the TT provided evidence that led to SA’s first ever TB conditional grant 196 
(ring fenced funds) for TB, and increased domestic funding for TB by R500m. Later that year, 197 
the TT provided evidence that informed the NTP decision to use ‘3HP’ preventative therapy 198 
for people living with HIV and child contacts, instead of ‘IPT’. Also in 2016, the TT provided 199 
evidence that supported the NTP decision to use Bedaquiline in the treatment of all multi-drug 200 
resistant TB patients. This evidence supported the recommendation in the NTP Strategic Plan 201 
that Bedaquiline be included in the MDR TB short-course regimen during the second phase 202 
of roll out (15). The Bedaquiline containing short course regimen will initially be implemented 203 
in centres of excellence under operational research conditions. The TT also took a leading 204 
role in supporting the NTP development of the new South Africa NTP Strategic Plan 2017-205 
2021. The TT convened meetings on the Plan, compiled and verified information from experts, 206 
and created a first draft of the Plan for NTP finalisation. The Plan has yet to be formally 207 
released, but will shape the TB response in South Africa for the next 5 years. The TT also has 208 
representation on the South African National AIDS council (SANAC) Steering Committee, a 209 
body bringing together government, civil society and the private sector to create a collective 210 
response to HIV, TB and STIs. The TT provided TB evidence for the new SANAC NSP, 211 
ensuring alignment with the NTP TB department’s Strategic Plan. 212 
 213 
Main challenges and enablers 214 
Although initial enthusiasm was high, motivating active and sustained participation from NTP 215 
and external experts proved challenging. From its initiation, it was evident that broad active 216 
participation of NTP staff was essential for the success of the TT. However, there were real 217 
constraints in terms of the amount of time that individual NTP staff could dedicate to the TT in 218 
the absence of a mandate from NTP leadership and/or provision of relief from other duties. 219 
The same was true of external experts. They were time constrained and were funded largely 220 
through grants and therefore the ability to provide substantial amount of unfunded time was 221 
limited. There was also a perception that the TT agenda was overly driven by key partners.  222 
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 223 
This then became the challenge to the Secretariat: to facilitate open and transparent TT calls 224 
and meetings that included robust and sustained NTP and external expert participation. 225 
  226 
Within one year of TT formation, it became evident to the Secretariat that the required level of 227 
stakeholder input would be hard to achieve. Due to scant participation at its programmed 228 
monthly teleconferences, the Secretariat abandoned the monthly format in favour of quarterly 229 
face-to-face meetings. 230 
  231 
Also evident was the need to flesh out robust agendas, to provoke vigorous discussion, and 232 
provide a platform for active decision making. There was a general perception that these 233 
quarterly TT meetings were to be different from typical TB conferences where researchers are 234 
asked to present their latest research work and findings to a general (TB) audience, with little 235 
required input from the audience. Rather, NTP staff and external experts demanded meeting 236 
agendas at which their targeted input was required in the form of yes/no votes on, for example, 237 
the implementation of Strategy A vs. Strategy B. 238 
  239 
Thus, the Secretariat worked with the TT co-chairs to create meeting agendas that identified 240 
the 2-3 highest priority items facing the NTP, e.g. whether ultraviolet lamps should be used for 241 
infection control, and the value of serological tests for diagnosis of Mycobacterium tuberculosis 242 
infection and TB disease. Once chosen, the Secretariat reached out to experts, collated the 243 
evidence required for presentation to the TT, and organised the meeting with the goal of 244 
provoking vigorous debate, but also consensus building and decision making. 245 
  246 
By reducing the frequency of the TT meetings to a quarterly format, and by focusing the 247 
agenda on 2-3 priority items requiring concrete input from its membership, the Secretariat 248 
could mobilise vigorous participation from both the NTP staff and external experts, and to 249 
channel this participation to result in concrete suggested paths of action for NTP strategy. 250 
 251 
The roles and activities of the TT greatly expanded over time in response to the needs of the 252 
NTP. First as a science-based ‘Institution’ – providing robust and independent evidence for 253 
policy formation, usually in response to an NTP request for rapid evidence. An example was 254 
providing evidence on potential use of 3HP therapy for people living with HIV and child 255 
contacts (Table 1). Second, as a ‘Policy Dialogue Forum’ facilitating the wider engagement 256 
between NTP and stakeholders on TB Policy. An example was facilitating the development of 257 
the NTP National Strategic plan (Table 1). Finally, as an ‘Interface’ between the NTP and the 258 
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modelling/economics community, where resource constraints limited the NTP’s ability to act 259 
as a critical consumer of research output.   260 
 261 
In addition, other enablers included strong political support from the South African President 262 
and Minister of Health, for improving TB prevention and care, core funding for convening 263 
activities and analytical work, and, over time, improving communication channels between the 264 
NTP, modellers, economists & other experts. 265 
 266 
Summary of independent evaluation, future directions and sustainability 267 
The TT was set up to be both demand-and supply-driven (i.e. responding to requests 268 
originating in the NTP but also investigating issues originated by its working parties).  269 
However, over time, it evolved towards the demand end of the spectrum. In response, its remit 270 
and processes have developed to find a balance that matches the national need.   271 
Key elements now need to be addressed to ensure the future sustainability and utility of the 272 
TT.  Perhaps most importantly, decision makers and funders should consider the balance the 273 
benefits of continuing to use the TT in its three roles (‘Institution’, ‘Policy Dialogue Forum’, and 274 
‘Interface’), against the risk that its resources will be spread too thinly and it will fail to deliver 275 
fully against any of them.   276 
Institutional role 277 
In its ‘Institutional’ role, the TT placed more emphasis on responding to government needs 278 
rather than proactively promoting the TT members’ analysis of key priorities. Under this model, 279 
the TT operated more as an integral part of the NTP policy development process; sponsored 280 
by it, but carrying out work at arm’s length from ministers. Although there are, as yet, only a 281 
few completed examples (i.e. development of policy briefs) the TT has shown it can be an 282 
independent body, supporting decision making by advising on issues put to it by Government.  283 
Improvements can be made: feedback from the NTP on decisions eventually taken often did 284 
not reach contributing experts, so it is essential in future to maintaining engagement and to 285 
help Members keep their advice relevant.  Some saw this reactive ‘Institution’ role as less 286 
valuable, but we propose this role may in fact be more critical over the long term, as it has the 287 
benefit of being aligned to the NTP’s expressed needs, and build the NTP’s trust and belief in 288 
the TT’s utility. We propose that the Working Groups could still originate issues under an 289 
institutional model. In addition, to further strengthen the ‘Institutional’ aspects of the TT, it could 290 
be structured in a similar way to other ‘arm’s length’ advice giving organisations like the 291 
National Institute of Clinical Excellence in the UK, and it may not want NTP ‘ownership’ which 292 
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may compromise its independence. Finally, for the ‘Institution’ to function more efficiently, we 293 
propose improved linkages between the TB TT and other TTs, particularly the HIV TT (11). 294 
Policy dialogue convener role 295 
The NTP encouraged the TT from the start to take on a significant ‘Policy Dialogue Convener’ 296 
role across initiatives and funders. In future, this could continue to be a major secondary 297 
benefit, but only if it is clear which organisation is responsible for which function or programme. 298 
This complementary policy dialogue role has proved very valuable to the NTP and National 299 
TB Strategic Plan stakeholders, including a wide variety of national institutions and NGOs,  300 
and deserves to be explicitly supported. However, if it is not covered explicitly in future funding 301 
agreements, we warn that the TT may end up doing the job anyway again, with consequences 302 
for both the quality of the dialogue and the TT’s other work. In addition, to further strengthen 303 
this role of the TT, we recommend the NTP needs to be enabled to take an increased 304 
ownership for the TT by taking on (or being seconded) a dedicated member of staff 305 
responsible for the TT. We also recommend external experts are better enabled to contribute 306 
to the TT, perhaps by funding their time directly, or with citeable acknowledgment of their 307 
contribution to the NTP decision making.  We recommend the TT is better integrated into the 308 
existing longer-term planning cycles in South Africa, as has occurred for the SANAC 2017-22 309 
National Strategic Plan.  There is also a need to change any perception that the TT agenda is 310 
overly driven by key partners, perhaps by diversifying the TT membership. Finally, the TT 311 
needs sustained funding, with a plan to transition to NTP funding over time. 312 
 Interface role 313 
In its third role, the TT has also provided value as an ‘Interface’ between the NTP and 314 
modelling initiatives, and provided resources where constraints limited the NTP’s ability to act 315 
as an ‘intelligent customer’ of analytical work. It helped the NTP formulate its requirements 316 
and interpreted/packaged modelling outputs for NTP use. However, TB modelling skills are 317 
extremely rare South Africa. As such we recommend that there is short term funding 318 
specifically to support TB modelling, until other South African institutions can maintain TB 319 
modelling expertise, so that the TT can draw on these skills when required for specific (usually 320 
short term) TT task. A grant commissioning management ability could also be included in the 321 
TT funding renewal to facilitate more engagement with a wider range of experts. 322 
 323 
Comparison with other Think Tank initiatives 324 
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There are similarities between the challengers, and enablers, identified in previous research 325 
on health policy TTs (9, 12), and in our study.  The SA TB TT was fortunate to have a 326 
supportive policy environment, some degree of independence from government, and strong 327 
links to policy makers, which facilitated effective policy engagement. Despite challenges, the 328 
SA TB TT also tended to provide timely, relevant, credible, trustworthy and actionable 329 
evidence to NTP, that further strengthened the relationship between the TT and NTP, over 330 
time.  The SA TB TT was also fortunate that, so far, it has only suffered temporary shortfalls 331 
in financial support, unlike the longer-term shortfalls experienced by TTs in Bangladesh, India, 332 
and Uganda and Indonesia (9, 12).  333 
 334 
Unlike the Indonesian TT (9), the SA TB TT’s evaluation focussed on the strategic and process 335 
level pre-conditions for impact on TB control, rather than practice level impacts. This was a 336 
deliberate decision, taken during TT creation, because it was thought impact on practice was 337 
unlikely over the ~ 2 years of the initial funding. However, given that alleviating suffering from 338 
TB (via changes in practice), is the SA TB TT’s ultimate goal, perhaps in the current funding 339 
cycle, the SA TB TT’s impact on practice, as well as policy, could be evaluated.  340 
 341 
We believe that the likely utility of this TT, and the contribution of other health policy TTs (9, 342 
12), justify their wider application to support evidence-informed TB decision making. Some 343 
key characteristics for effective engagement and practical delivery have now been identified, 344 
and many aspects of the South African TT model could be replicated in other settings. 345 
 346 
  347 
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CONCLUSION 348 
The TB TT, with partners, yielded major successes in supporting evidence-informed decision 349 
making, and garnered increased funding for TB in South Africa. Identifying ways to increase 350 
involvement of NTP staff & other experts, and keeping the scope of the TT well defined, could 351 
facilitate greater impact. TT initiatives could be replicated in other settings to support evidence-352 
informed policymaking. 353 
  354 
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BOX, TABLES AND FIGURES 414 
Box – Illustrative example of Think Tank Processes – Childhood screening for TB 415 
In 2014, the TB Think Tank was requested by the South African National Department of 416 
Health to provide recommendations on whether screening of children in schools was an 417 
appropriate intervention.  A policy brief was compiled, based on review of key publications, 418 
and input from experts from at least three different institutions: 419 
 420 
1. The national data were reviewed to determine the proportion of notified TB cases 421 
nationally among children.  It was determined that paediatric (<15 years) cases of TB 422 
made up 11% of notified TB cases, and that approximately 50% of these were in children 423 
under 5 years of age.  424 
 425 
2. TB Prevalence studies, undertaken as part of TB vaccine studies, were reviewed to 426 
determine the TB prevalence in different child populations.  It was determined that TB 427 
prevalence amongst adolescents was very low, at 0.3%, indicating that active case 428 
finding in this group would not yield a high number of TB cases.  In infants, M.tb infection 429 
prevalence was around 5.3%. 430 
 431 
3. Further evidence for screening of children among TB household contacts was reviewed 432 
to determine the most appropriate intervention for identifying TB.   433 
 434 
4. All additional considerations were listed such as: 435 
 Higher prevalence of more severe TB types such as TB meningitis among children 436 
 Difficulty in diagnosis of TB in children 437 
 Reduced transmission from children therefore limited public health benefit. 438 
 439 
The recommendation to the National TB department was that TB in children accounts for a 440 
small proportion of the national burden of TB.  There was little evidence to suggest that 441 
school based education and active case finding in schools will impact on the national TB 442 
epidemic.   443 
 444 
The National TB department then decided to focus their case-finding interventions on 445 
creches (children under five), rather than schools. 446 
  447 
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 448 
Wide range of stakeholders and experts invited to face-to-face quarterly meetings
Executive committee linked to SA Finance department, and supported by SA and international 
research and policy institutions. 
Executive Committee
Chair: Deputy Director General for 
Health Strategy 
Co-Chair: SA Research Institute Head
Working group 1: 
Modernizing TB response
Working group 2: 
Implementation and delivery
Working group 3: 
New tools: diagnostics, drugs 
and vaccine
Secretariat: 
SA Research Institute
 449 
Fig 1 Current organizational structure of the South Africa TB Think Tank. SA = South 450 
Africa. TB = tuberculosis.  451 
 452 
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TABLE 1 Examples of likely policy influence of TB Think Tank 2014-16. TT = Think Tank. SA = South Africa. TB = tuberculosis, MRC = 453 
Medical Research Council, NTP = National Tuberculosis Programme, UNAIDS = Joint United Nations Programme on HIV/AIDS, ICF= 454 
Intensified Case Finding, IC = Investment case, 3HP =  Once-weekly isoniazid and rifapentine for 3 months, IPT = Isoniazid preventive therapy, 455 
PLWHIV = People Living with HIV/AIDS, BDQ = Bedaquiline, MDR = Multi-drug-resistant, WHO= World Health Organization, NTP = National 456 
TB Programme, NICD = National Institute for Communicable Diseases , URC = University Research Co, SAMRC = South Africa MRC, NHLS = 457 
National Health Laboratory Service, SANAC = South African National Aids Council, USAID = U.S. Agency for International Development, CDC 458 
= Centers for Disease Control and Prevention, NGO = non-governmental organization. 459 
 460 
Policy area Policy output  Timeframe 
of 
influence  
Key actor (other 
stakeholders) 
Key Think Tank 
activities  
Impact  Evidence for Impact  
SA MRC 
research 
funding 
Funding call 2014/5 SA MRC, MRC 
UK 
Data analysis, 
modelling, call & 
presentation to SA 
MRC 
TT provided evidence that helped 
define scope of SAMRC/ UKMRC 
funding call on operational research 
(R70m) 
Presentation to SAMRC   
Funding call on SAMRC 
website 
NTP TB 
screening 
policy 
Childhood TB 
screening policy 
brief 
2014/5 NTP, 
Researchers 
Development of Policy 
Brief 
Change in strategy with regards TB 
screening for children 
Active case-finding practice 
in under 15s 
SA funding 
for research 
NTP decision to 
support 
2015+ SA MRC, NTP Meeting convening TT asked to convene meetings & 
develop concept until NTP 
supported National TB Research 
Plan and Investment Case for TB 
Research. Now MRC led. 
Meeting notes 
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Policy area Policy output  Timeframe 
of 
influence  
Key actor (other 
stakeholders) 
Key Think Tank 
activities  
Impact  Evidence for Impact  
NTP TB 
funding 
SA TB & HIV 
Investment Case 
(first ever) 
2015+ UNAIDS 
(SANAC, NTP 
NTP, Treasury) 
Analysis, modelling and 
report preparation 
TT provided evidence that led to 
change in NTP budgets for TB in 
2016. IC phase II results form the 
basis of ICF recommendations in 
NTP strategy 2016. 
IC Phase I report on SANAC 
website 
IC overview presented to Dr 
Lindiwe Mvusi 
Key IC Phase II findings for 
NTP, presented to TT 
NTP TB 
funding 
SA conditional grant 
(ring fenced funds) 
for TB (first ever) 
2016+ UNAIDS 
(SANAC, NTP 
NTP, Treasury) 
Analysis, modelling, 
presentation to the NTP 
to inform parliamentary 
budget bid 
TT provided evidence that led to 
SA’s first ever TB conditional grant 
(ring fenced funds) for TB and 
increased domestic funding for TB 
(R500m). TT has assisted with 
collecting information on current TB 
expenditure and supplying unit 
costs for conditional grant provincial 
business plans. 
Cost model 
NTP presentations 
Budget bid 
Letter from Deputy Director 
General for Health Strategy 
NTP TB 
treatment 
policy 
Policy and NTP 
strategy 
2016+ National Health 
Committee 
Developed 3HP 
component of the 
National TB Strategic 
Plan and co-led the 
development of the 
NTP Strategic plan 
TT provided evidence to support 
NTP justification to use 3HP, 
instead of IPT, for PLWHIV/ child 
contacts 
3HP included in the NTP 
Strategic Plan (draft). 
Letter from Deputy Director 
General for Health Strategy 
NTP TB 
treatment 
policy 
Policy and NTP 
strategy 
2016+ NTP, National 
Health 
Committee 
Convened an expert 
working group to review 
the evidence from the 
Bedaquiline (BDQ) 
TT provided evidence that 
supported the NTP decision to use 
Bedaquiline in the treatment of all 
multi-drug resistant TB patients. 
SA Data from BCAP and 
National rollout program 
presented to WHO by TT, to 
be included in the individual 
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Policy area Policy output  Timeframe 
of 
influence  
Key actor (other 
stakeholders) 
Key Think Tank 
activities  
Impact  Evidence for Impact  
clinical access 
programme and the 
national rollout data to 
evaluate the effect of 
BDQ on mortality. 
Facilitated engagement 
with WHO. Facilitated 
inclusion of BDQ in the 
short course MDR TB in 
the National Strategic 
Plan 
This evidence supported the 
recommendation in the NTP 
Strategic Plan that Bedaquiline be 
included in the MDR TB short-
course regimen during the second 
phase of roll out. The Bedaquiline 
containing short course regimen will 
initially be implemented in centres of 
excellence under operational 
research conditions 
level meta-analysis of BDQ 
effectiveness and safety 
commissioned by WHO. TT 
also facilitated inclusion of 
BDQ in the short course 
regimen in the NTP Strategic 
Plan (draft). Meeting 
minutes. 
Letter from Deputy Director 
General for Health Strategy 
National TB 
prevention 
and care 
strategy and 
resource 
allocation 
NTP Strategic Plan, 
2017-2021 
2017-2021 NTP, NICD, 
URC, SAMRC, 
NHLS, SANAC, 
USAID, CDC   
Meeting convener, note 
taker, document writing, 
sub-group hosting, 
compiler and verifier of 
information.   
 
Forthcoming Meeting report: 19-20/4/16 
NTP costing analysis 
NTP Strategic Plan (draft) 
Letter from Deputy Director 
General for Health Strategy 
National TB 
prevention 
and care 
strategy and 
resource 
allocation  
SANAC national 
strategic plan 
document 
2017-2022 SANAC, NTP,  
Civil Society 
Development,  
Partners,  
NGOs 
Representation on NSP 
Steering Committee 
Participation at NSP 
consultation meetings 
and workshops 
Forthcoming SANAC final report 
Letter from Deputy Director 
General for Health Strategy 
 461 
